[1] ZAFRANI ES. Non-alcoholic fatty liver disease：an emerging pathological spectrum[J]. Virchows Arch,2004,444（1）：3-12.
[2] 高爱滨,肖谦. PPARα与非酒精性脂肪肝[J]. 国际消化病杂志,2007,27（1）：18-21.
[3] ANAI M,FUNAKI M,OGIHARA T,et a1. Altered expression levels and impaired steps in the pathway to phosphatidylinositol 3-kinase activation via insulin receptor substrates 1 and 2 in Zucker fatty rats[J]. Diabetes,1998,47（1）：13-23.
[4] GRIFFINN ME,MARCUCCI MJ,CLINE GW,et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade[J]. Diabetes,1999,48（6）：1270-1274.
[5] BODEN G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM[J]. Diabetes,1997,46（1）：3-10.
[6] POLYZOS SA,KOUNTOURAS J,ZAVOS C. Nonalcoholic fatty liver disease：the pathogenetic roles of insulin resistance and adipocytokines[J]. Curr Mol Med,2009,9（3）：299-314.
[7] 杨丽丽,柳涛,王淼,等. 氧化应激与非酒精性脂肪性肝病研究进展[J]. 世界华人消化杂志,2009,17（9）：896-900.
[8] GARCIA-ROVES P,JANICE MH,DONG HH,et al. Raising plasma fatty acid concentration induces increased biogenesis of mitochondria in skeletal muscle[J]. PNAS,2007,104（25）：10709-10713.
[9] CHAKRABARTI R,VIKRAMADITHYAN RK,MISRA P,et al. Ragaglitazar：a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models[J]. Br J Pharmacol,2003,140（3）：527-537.
[10] BAUMGARDNER JN,SHANKAR K,HENNINGS L,et al. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet[J]. Am J Physiol Gastrointest Liver Physio,2008,294：G27-G38.
[11] EVERETT L,GALII A,CRABB D. The role of hepatic peroxisome proliferator activated receptors（PPARs） in health and disease[J]. Liver,2000,20（3）：191-199.
[12] YANYAN ZOU,HUI DU,MIAO YIN,et al. Effects of high dietary fat and cholesterol on expression of PPARα,LXRα,and their responsive genes in the liver of apoE and LDLR double deficient mice[J]. Mol Cell Biochem,2009,323：195-205.
[13] 毛刘锋,姜小伟,秦艳,等. 内质网应激对2型糖尿病小鼠脂肪肝发生的影响[J]. 世界华人消化杂志,2009,17（1）：4-10.
[14] JEONG-A KIM,YONGZHONG WEI,JAMES R. SOWERS. Role of mitochondrial dysfunction in insulin resistance[J]. Circ Res,2008,102：401-414.
[15] GOCHEE PA,JONSSON JR,CLOUSTON AD,et a1. Steatosis in chronic hepatitis C：association with increased messenger RNA expression of collagen I,tumor necrosis factor-alpha and cytochrome P450 2E1[J]. J Gastroenterol Hepatol,2003,18（4）：386-392.
[16] KOHJIMA M,ENJOJI M,HIGUCHI N,et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease[J]. Int J Mol Med,2007,20（3）：351-358.
[17] CAROLINE R,MARIE-ASTRID P,DOMINIQUE L,et al. Mitochondrial adaptations to steatohepatitis induced by a methionine-and choline-deficient diet[J]. Am J Physiol Endocrinol Metab,2008,294：E110-E119.
[18] PROMRAT K,LUTCHMAN G,UWAIFO GI,et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis[J]. Hepatology,2004,39（1）：l88-196.
[19] PORTINCASA P,GRATTAGLIANO I,PALMIERI VO,et a1. Nonalcoholic steatohepatitis：recent advances from experimental models to clinical management[J]. Clin Biochem,2005,38（3）：203-217.
[20] 邵亮,韩真. 非酒精性脂肪肝的药物治疗进展[J]. 实用肝脏病杂志,2006,9（2）：121-124. |
